Castle Bioscience closed a $20M Series F round of financing, led by Industry Ventures, with HealthQuest and other existing investors participating. The latest financing will help Castle add commercial infrastructure to meet demand for the company's cutaneous melanoma test and fund ongoing projects and general purposes, Maetzold said. "Our expectation in the next two to three years is that the cutaneous melanoma test will continue to work its way into the standard of care. In 2017, we'll have 5 to 6 proprietary high value clinical tests," he said.